FY2017 EPS Estimates for CVS Health Corp (CVS) Boosted by Leerink Swann

CVS Health Corp (NYSE:CVS) – Stock analysts at Leerink Swann raised their FY2017 earnings per share estimates for CVS Health in a research note issued on Monday. Leerink Swann analyst D. Larsen now anticipates that the pharmacy operator will post earnings per share of $5.90 for the year, up from their previous estimate of $5.88. Leerink Swann currently has a “Outperform” rating and a $90.00 target price on the stock. Leerink Swann also issued estimates for CVS Health’s Q4 2017 earnings at $1.90 EPS, Q1 2018 earnings at $1.31 EPS, Q2 2018 earnings at $1.63 EPS and Q3 2018 earnings at $1.91 EPS.

Other research analysts have also issued reports about the stock. Royal Bank of Canada assumed coverage on shares of CVS Health in a research report on Tuesday, September 19th. They set an “outperform” rating and a $95.00 price target on the stock. Jefferies Group raised their price target on shares of CVS Health from $82.00 to $86.00 and gave the company a “hold” rating in a research report on Friday, September 15th. ValuEngine lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Robert W. Baird reissued a “hold” rating and set a $77.00 price target on shares of CVS Health in a research report on Friday, October 27th. Finally, Mizuho set a $90.00 price target on shares of CVS Health and gave the company a “buy” rating in a research report on Tuesday, October 24th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $86.66.

CVS Health (CVS) opened at $77.69 on Tuesday. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. CVS Health has a 12-month low of $66.45 and a 12-month high of $84.72. The firm has a market cap of $78,700.00, a PE ratio of 16.05, a P/E/G ratio of 1.38 and a beta of 0.90.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. During the same period last year, the firm earned $1.64 earnings per share. The business’s quarterly revenue was up 3.5% compared to the same quarter last year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.57%. The ex-dividend date of this dividend is Tuesday, January 23rd. CVS Health’s dividend payout ratio is 41.32%.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of CVS Health stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the sale, the executive vice president now owns 15,556 shares of the company’s stock, valued at $1,166,700. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.61% of the company’s stock.

A number of hedge funds have recently made changes to their positions in CVS. FMR LLC increased its stake in shares of CVS Health by 22.0% in the second quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock worth $2,425,920,000 after purchasing an additional 5,446,930 shares in the last quarter. Truepoint Inc. increased its stake in shares of CVS Health by 8,578.9% in the third quarter. Truepoint Inc. now owns 3,757,530 shares of the pharmacy operator’s stock worth $3,758,000 after purchasing an additional 3,714,235 shares in the last quarter. Boston Partners increased its stake in shares of CVS Health by 69.1% in the second quarter. Boston Partners now owns 6,459,237 shares of the pharmacy operator’s stock worth $519,711,000 after purchasing an additional 2,638,888 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of CVS Health by 30.2% in the third quarter. Ameriprise Financial Inc. now owns 7,977,370 shares of the pharmacy operator’s stock worth $648,683,000 after purchasing an additional 1,849,593 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its stake in shares of CVS Health by 71.5% in the second quarter. Parametric Portfolio Associates LLC now owns 3,949,854 shares of the pharmacy operator’s stock worth $317,805,000 after purchasing an additional 1,647,168 shares in the last quarter. 81.62% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “FY2017 EPS Estimates for CVS Health Corp (CVS) Boosted by Leerink Swann” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.com-unik.info/2018/01/10/fy2017-eps-estimates-for-cvs-health-corp-cvs-boosted-by-leerink-swann.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit